CYP2C19*2、*3无功能型等位基因对汉族与维吾尔族患者经皮冠状动脉支架植入术后使用氯吡格雷的疗效影响

高方明; 宋博凡

doi:10.13898/j.cnki.issn.1000-2200.2016.12.026

CYP2C192、3无功能型等位基因对汉族与维吾尔族患者经皮冠状动脉支架植入术后使用氯吡格雷的疗效影响

新疆维吾尔自治区人民医院心内科, 新疆乌鲁木齐 830001

作者简介: 高方明(1962-),男,教授,主任医师.

中图分类号: R541.4

Effect of the CYP2C19 2,3 non-functional allele on the curative effect of clopidogrel after PCI in Han and Uygur patients

Department of Cardiology, The People's Hospital of Uiger Autonomous Region, Urumqi Xinjiang 830001, China
CLC number: R541.4

摘要: 目的：探讨携带CYP2C19*2、*3无功能型等位基因的汉族和维吾尔族患者经皮冠状动脉支架植入术（PCI）后口服氯吡格雷的疗效差异。方法：前瞻性纳入确诊为急性冠状动脉综合征并行PCI术患者400例，根据CYP2C19基因检测结果分为氯吡格雷正常代谢组（A组）与氯吡格雷弱代谢组（B组）。A组患者术后常规给予75 mg氯吡格雷，B组给予150 mg氯吡格雷。均随访（30±3）d，以再发急性心肌梗死、再发心绞痛、心源性猝死、支架内再血栓、非致死性卒中、致命性和危及生命出血事件为主要终点事件，以次要出血和轻微出血为次要终点事件，比较2组终点事件发生率。结果：A组中汉族患者与维吾尔族患者再发心肌梗死发生率（2.34%与1.47%）、再发心绞痛发生率（6.25%与5.88%）、心源性猝死（0.78%与0.00%）、支架内再血栓（1.56%与0.00%）及出血事件的发生率（5.47%与7.35%）差异均无统计学意义（P>0.05）；B组中汉族患者与维吾尔族患者再发急性心肌梗死发生率（1.87%与0.00%）、再发心绞痛发生率（5.61%与4.76%）及出血事件的发生率（3.74%与4.76%）差异均无统计学意义（P>0.05），且均无心源性猝死、支架内再血栓、非致死性卒中、致命性与危及生命出血事件发生。2组维吾尔族患者再发急性心肌梗死发生率（0.00%与1.47%）、再发心绞痛发生率（4.76%与5.88%）及出血事件发生率（4.76%与7.35%）差异均无统计学意义（P>0.05），且均无心源性猝死、支架内再血栓、非致死性卒中、致命性与危及生命出血事件发生。结论：携带CYP2C19*2、*3无功能型等位基因的维吾尔族患者口服150 mg/d氯吡格雷可减弱氯吡格雷抵抗，有效减少主要心血管事件发生率，且不增加出血风险。
- 急性冠状动脉综合征 /
- CYP2C19*2基因 /
- CYP2C19*3基因 /
- 氯吡格雷 /
- 药物抵抗 /
- 经皮冠状动脉支架植入术
Abstract: Objective: To compare the effects of the CYP2C19 *2,*3 non-functional allele on the curative effect of clopidogrel after percutaneous coronary stent implantation(PCI) between Han and Uygur patients.Methods: Four hundred acute coronary syndrome patients treated with PCI were divided into the clopidogrel normal metabolish group(group A) and weak clopidogrel normal metabolish group(group B) according to the result of CYP2C19 genetic testing.The group A and group B were treated with 75 mg and 150 mg of clopidogrel,respectively.Two groups were followed up for (30±3)d.The recurrences of the acute myocardial infarction,angina,cardiac death,stent thrombosis,nonfatal stroke,fatal and life-threatening bleeding were the primary endpoint events,and the minor bleeding and slight bleeding were the secondary endpoint events.The incidence of the endpoint event between two groups were compared.Results: The differences of the recurrence rate of the acute myocardial infarction(2.34% and 1.47%),angina(6.25% and 5.88%),cardiac death(0.78% and 0.00%),stent thrombosis(1.56% and 0.00%),and bleeding(5.47% and 7.35%) between Han and Uygur patients in group A were not statistically significant(P>0.05).The differences of the recurrence rate of the acute myocardial infarction(1.87% and 0.00%),angina(5.61% and 4.76%) and bleeding(3.74% and 4.76%) between Han and Uygur patients in group B were not statistically significant(P>0.05),and the cardiac death,stent thrombosis,nonfatal stroke,fatal and life-threatening bleeding were not found in Han and Uygur patients of group B.The differences of the recurrence rate of the acute myocardial infarction,angina and bleeding in Uygur patients between group A and group B were not statistically significant(P>0.05),and the cardiac death,stent thrombosis,nonfatal stroke,fatal and life-threatening bleeding were not found in Uygur patients of group A and group B.Conclusions: Among Uighur patients with the CYP2C19*2,*3 non-functional allele,the treatment of 150mg of clopidogrel per day can weaken the clopidogrel resistance,effectively reduce the incidence of major cardiovascular events,and does not increase the risk of bleeding.
- acute coronary syndrome /
- CYP2C19*2 gene /
- CYP2C19*3 gene /
- clopidogrel /
- drug resistance /
- percutaneous coronary stent implantation

[1]	TRESUKOSOL D,SUKTITIPAT B,HUNNANGKUL S,et al.Effects of cytochrome P4502C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease[J].PLoS One,2014,9(10):87.
[2]	JANG JS,CHO KI,JIN HY,et al.Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel[J].Am J Cardiol,2012,110(4):502.
[3]	CHEN DY,WANG CY,WEN MS,et al.Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population [J].PLoS One,2012,7(6):102.
[4]	BARKER CM,MURRAY SS,TEIRSTEIN PS,et al.Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity[J].JACC Cardiovasc Interv,2010,3(10):1008.
[5]	MEHTA SR,YUSUF S,PETERS RJ,et al.Effects of pretreatment with elopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:the PCI-CURE study[J].Lancet,2001,358(9281):527.
[6]	MEHTA SR,TANGUAY JF,EIKELBOOM JW,et al.Double-dose versus standard-dose elopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes:a randomised factorial trial[J].Lancet,2010,376(9748):1233.
[7]	TERPENING C.Clopidogrel:a pharmacogenormic perspective on its use in coronary artery disease[J].Clin Med Insights Cardiol,2010,4:117.
[8]	PRICE MJ,MURRAY SS,ANGIOLILLO DJ,et al.Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention:the GIFT (GenotypeInformation and Functional Testing) study[J].Am Coll Cardiol,2012,59(22):1928.
[9]	WU H,QIAN J,SUN A,et al.Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment [J].Circ,2012, 76(12):2773.
[10]	ZHANG L,CHEN Y,JIN Y,et al.Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients[J].Thromb Res,2013,132(1):81.
[11]	TAUBERT D,BOUMAN HJ,VAN WERKUM JW,et al.Cytochrome P-450 polymorphisms and response to clopidogrel[J].N Engl J Med,2009,360(4):354.
[12]	COLLET JP,HULOT JS,ANZAHA G,et al.High doses of clopidogrel to overcome genetic resistance:the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2)[J].JACC Cardiovas Interv,2011,4(4):392.
[13]	MEGA JL,HOCHHOLZER W,FRELINGER AL,et al.Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease[J].JAMA,2011,306(20):2221.
[14]	CUISSET T,QUILICI J,COHEN W,et al.Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome[J].Am J Cardiol,2011,108(6):760.
[15]	JEONG YH,KIM IS,PARK Y,et al.Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day:results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study[J].JACC Cardiovasc Interv,2010,3(7):731.
[16]	PARK J.Backtracking on CYP2C19 genotyping in clopidogrel therapy?[J].Biomark Med,2010,363(18):1704.

[1]	后世翔 , 方存明 , 栾家杰 , 王敏 . CYP2C19、ABCB1和PON1基因多态性对ACS病人PCI术后氯吡格雷治疗的影响. 蚌埠医学院学报, 2021, 46(5): 606-610. doi: 10.13898/j.cnki.issn.1000-2200.2021.05.012
[2]	骆嵩 , 杨丽娟 , 屈洪党 . 氯吡格雷治疗急性脑梗死病人CYP2C19基因多态性检测的临床意义. 蚌埠医学院学报, 2018, 43(9): 1136-1139. doi: 10.13898/j.cnki.issn.1000-2200.2018.09.005
[3]	张玉惠 , 刘俊 , 陈金国 , 张军 , 沈童童 . 替格瑞洛与氯吡格雷对急性冠状动脉综合征患者血小板聚集的对比分析. 蚌埠医学院学报, 2016, 41(6): 733-735,738. doi: 10.13898/j.cnki.issn.1000-2200.2016.06.009
[4]	汝鹏 , 李玉喜 . 急性冠状动脉综合征病人血清中超敏肌钙蛋白、超敏C反应蛋白和同型半胱氨酸水平变化及临床意义. 蚌埠医学院学报, 2019, 44(6): 758-760, 764. doi: 10.13898/j.cnki.issn.1000-2200.2019.06.017
[5]	夏永梅 , 于玲 , 李兰君 , 刘春艳 , 叶红晖 . 阿托伐他汀联合氯吡格雷及拜阿司匹林对进展性脑梗死患者颈动脉粥样硬化的疗效评价. 蚌埠医学院学报, 2016, 41(3): 337-339. doi: 10.13898/j.cnki.issn.1000-2200.2016.03.018
[6]	高晓洁 , 季梅丽 , 杨阳 , 俞颖 . 延续护理对经皮冠状动脉支架植入术后患者自我护理能力及健康行为的影响. 蚌埠医学院学报, 2014, 39(12): 1714-1717.
[7]	方淑玲 , 杨茹 , 赵芙蓉 , 姚桐青 , 朱应玉 . 性知识教育对中青年男性冠心病病人经皮冠状动脉支架植入术后生活质量及性功能的影响. 蚌埠医学院学报, 2020, 45(7): 958-960. doi: 10.13898/j.cnki.issn.1000-2020.07.031
[8]	范婷婷 , 何非 , 王晓晨 . 高密度脂蛋白3与急性冠状动脉综合征相关性临床分析. 蚌埠医学院学报, 2019, 44(10): 1319-1321. doi: 10.13898/j.cnki.issn.1000-2200.2019.10.007
[9]	汤阳 , 朱飞宇 , 孙硕 , 戎李 , 赵懿 , 张恒 , 高琴 , 康品方 . RIP1-RIP3-MLKL信号通路在急性冠状动脉综合征病人外周血单核细胞中的表达. 蚌埠医学院学报, 2022, 47(4): 447-451. doi: 10.13898/j.cnki.issn.1000-2200.2022.04.006
[10]	袁凤云 , 刘岩红 . 氯吡格雷联合拜阿司匹林治疗高龄急性脑梗死病人效果. 蚌埠医学院学报, 2019, 44(6): 765-768. doi: 10.13898/j.cnki.issn.1000-2200.2019.06.019
[11]	王茂林 , 祖磊 , 石世强 . 氯吡格雷联合阿司匹林治疗冠心病合并eGFR降低病人的药物敏感性分析. 蚌埠医学院学报, 2021, 46(3): 343-345. doi: 10.13898/j.cnki.issn.1000-2200.2021.03.017
[12]	孙彤 , 程仁力 , 尤家聪 , 范玲珑 , 周争光 , 丁书梅 , 唐海沁 . 急性ST段抬高型心肌梗死PCI术后使用双倍剂量氯吡格雷的效果观察. 蚌埠医学院学报, 2016, 41(2): 217-219. doi: 10.13898/j.cnki.issn.1000-2200.2016.02.026
[13]	谢静 , 叶明 , 刘东亮 , 许娟娟 , 许力 , 刘晓林 , 孙中武 . 氯吡格雷联合拜阿司匹林对老年急性脑梗死病人疗效及对细胞炎症因子、凝血功能的影响. 蚌埠医学院学报, 2019, 44(8): 1009-1011. doi: 10.13898/j.cnki.issn.1000-2200.2019.08.008
[14]	郭仕俊 , 苏令 , 章福彬 , 孙磊 . 氯吡格雷联合肠溶性阿司匹林在急性心肌梗死治疗中的应用. 蚌埠医学院学报, 2017, 42(4): 458-461. doi: 10.13898/j.cnki.issn.1000-2200.2017.04.012
[15]	张桂华 . 急性冠状动脉综合征相关细胞因子研究进展. 蚌埠医学院学报, 2009, 34(7): 650-653.
[16]	郭荣贞 . 急性冠状动脉综合征9例急救与护理体会. 蚌埠医学院学报, 2011, 36(1): 86-87.
[17]	华启洋 , 张宁汝 , 周桂建 , 张恒 . 血清内脂素与急性冠状动脉综合征的相关性. 蚌埠医学院学报, 2011, 36(12): 1341-1342,1345.
[18]	吕新才 . 急性冠状动脉综合征患者心电图U波倒置与冠状动脉病变的相关性. 蚌埠医学院学报, 2016, 41(2): 185-187,190. doi: 10.13898/j.cnki.issn.1000-2200.2016.02.015
[19]	王廷涛 , 张效明 , 张俊 , 刘群 , 武文君 , 陈燕 , 熊守庆 . 急性冠状动脉综合征的炎症机制及氟伐他汀的抗炎作用. 蚌埠医学院学报, 2009, 34(6): 501-503.
[20]	李勇 . 二级医院急性冠状动脉综合征治疗现状与指南的差距. 蚌埠医学院学报, 2011, 36(8): 820-822.

点击查看大图

计量

文章访问数: 3385
HTML全文浏览量: 427
PDF下载量: 75
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

CYP2C192、3无功能型等位基因对汉族与维吾尔族患者经皮冠状动脉支架植入术后使用氯吡格雷的疗效影响

作者简介: 高方明(1962-),男,教授,主任医师.

Effect of the CYP2C19 2,3 non-functional allele on the curative effect of clopidogrel after PCI in Han and Uygur patients

计量

CYP2C192、3无功能型等位基因对汉族与维吾尔族患者经皮冠状动脉支架植入术后使用氯吡格雷的疗效影响

作者简介: 高方明(1962-),男,教授,主任医师.

English Abstract

Effect of the CYP2C19 2,3 non-functional allele on the curative effect of clopidogrel after PCI in Han and Uygur patients

全文HTML

目录

留言板

CYP2C19*2、*3无功能型等位基因对汉族与维吾尔族患者经皮冠状动脉支架植入术后使用氯吡格雷的疗效影响

作者简介: 高方明(1962-),男,教授,主任医师.

Effect of the CYP2C19 *2,*3 non-functional allele on the curative effect of clopidogrel after PCI in Han and Uygur patients

计量

出版历程

CYP2C19*2、*3无功能型等位基因对汉族与维吾尔族患者经皮冠状动脉支架植入术后使用氯吡格雷的疗效影响

作者简介: 高方明(1962-),男,教授,主任医师.

English Abstract

Effect of the CYP2C19 *2,*3 non-functional allele on the curative effect of clopidogrel after PCI in Han and Uygur patients

全文HTML

目录

CYP2C192、3无功能型等位基因对汉族与维吾尔族患者经皮冠状动脉支架植入术后使用氯吡格雷的疗效影响

Effect of the CYP2C19 2,3 non-functional allele on the curative effect of clopidogrel after PCI in Han and Uygur patients

CYP2C192、3无功能型等位基因对汉族与维吾尔族患者经皮冠状动脉支架植入术后使用氯吡格雷的疗效影响

Effect of the CYP2C19 2,3 non-functional allele on the curative effect of clopidogrel after PCI in Han and Uygur patients